S. et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30198-0 (2018) Article PubMed Google Scholar Download ...
177Lu‐PSMA‐617 radioligand therapy and outcome in patients with metastasized castration‐resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1663‐1670.Brauer A, Grubert LS, Roll W, Schrader AJ, Schafers M, Bogemann M, Rahbar K. 177Lu-PSMA-617 radioligand therapy and outcome ...
A decline in prostate-specific antigen (PSA) of ≥50% occurred in 53%, and a decline in PSA of any amount in 91% of patients. The estimated median OS was 32 weeks. An initial alkaline phosphatase (ALP) level 177Lu-PSMA-617 and an initial ALP level <220 U/L were predictors of...
This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). The contribution of pretreatment risk factors and cumulative treatment activity is taken into ...
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol ... Sahoo,Ranjit,Kumar,... - 《European Journal of Nuclear Medicine & Molecular Imaging》 被引量: 0发表: 2017年 Lu-177-DKFZ-PSMA-617 therap...
(5.0–11.6)GBq.Significantresponderstotandemtherapyreceived177Lu-PSMA-617monotherapyasmaintenance(median[minimum–maximum]:1[0–5]cycle).Afteramedian(minimum–maximum)22(14–63)weeks’follow-up,13/20patients(65%)hadasbestbiochemicalresponseaPSAdecline>50%.Median(95%confidenceinterval)progression-free...
The recent phase III VISION-trial confirms the treatment efficacy of radioligand therapy with [177Lu]PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate cancer (mCRPC). In PSMA-RLT, the relatively low absorbed bone marrow dose allows for mult
在VISION中,17.4%的患者在177Lu-PSMA之前接受了223Ra治疗,未对疗效产生不良影响,但该亚组的安全性尚未报告(5)。然而,回顾性研究表明,在177Lu-PSMA之前使用223Ra是可行的,具有可接受的安全性(6,7)。此外,在进行性骨转移疾病的患者...
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
They also found a rapid decline of activity in the arm and a normal distribution of [177Lu]Lu-PSMA after 20 h. Furthermore, the reports of skin burns [14] and development of subcutaneous squamous carcinoma [5] after extravasation with the small molecules [131I]I-metaiodbenzylguanidine (...